Vinva Investment Management Ltd Acquires Shares of 2,893 Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Vinva Investment Management Ltd acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 2,893 shares of the biopharmaceutical company’s stock, valued at approximately $138,000.

Several other institutional investors also recently bought and sold shares of HALO. GSA Capital Partners LLP acquired a new position in Halozyme Therapeutics in the 3rd quarter valued at $217,000. CIBC Asset Management Inc acquired a new position in Halozyme Therapeutics in the 3rd quarter valued at $211,000. Natixis Advisors LLC increased its stake in Halozyme Therapeutics by 86.7% in the 3rd quarter. Natixis Advisors LLC now owns 121,560 shares of the biopharmaceutical company’s stock valued at $6,958,000 after buying an additional 56,461 shares during the period. Quest Partners LLC increased its stake in Halozyme Therapeutics by 1,386.0% in the 3rd quarter. Quest Partners LLC now owns 9,793 shares of the biopharmaceutical company’s stock valued at $561,000 after buying an additional 9,134 shares during the period. Finally, B. Metzler seel. Sohn & Co. Holding AG acquired a new position in Halozyme Therapeutics in the 3rd quarter valued at $1,899,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. Wells Fargo & Company lowered their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Piper Sandler upped their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Finally, Benchmark reaffirmed a “buy” rating and set a $75.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $62.78.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $58.69, for a total value of $293,450.00. Following the transaction, the director now directly owns 33,611 shares in the company, valued at approximately $1,972,629.59. This represents a 12.95 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Michael J. Labarre sold 1,697 shares of the company’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the transaction, the senior vice president now owns 173,756 shares in the company, valued at approximately $10,126,499.68. This trade represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 31,697 shares of company stock worth $1,754,451. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock opened at $65.16 on Friday. Halozyme Therapeutics, Inc. has a 52 week low of $37.73 and a 52 week high of $65.53. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. The firm’s 50-day simple moving average is $58.20 and its 200 day simple moving average is $54.76. The firm has a market capitalization of $8.02 billion, a PE ratio of 19.00, a P/E/G ratio of 0.42 and a beta of 1.32.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, topping the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The business had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. On average, equities research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.